| Literature DB >> 23907534 |
Lars Jørgensen1, Steven J McKerrall, Christian A Kuttruff, Felix Ungeheuer, Jakob Felding, Phil S Baran.
Abstract
Ingenol is a diterpenoid with unique architecture and has derivatives possessing important anticancer activity, including the recently Food and Drug Administration-approved Picato, a first-in-class drug for the treatment of the precancerous skin condition actinic keratosis. Currently, that compound is sourced inefficiently from Euphorbia peplus. Here, we detail an efficient, highly stereocontrolled synthesis of (+)-ingenol proceeding in only 14 steps from inexpensive (+)-3-carene and using a two-phase design. This synthesis will allow for the creation of fully synthetic analogs of bioactive ingenanes to address pharmacological limitations and provides a strategic blueprint for chemical production. These results validate two-phase terpene total synthesis as not only an academic curiosity but also a viable alternative to isolation or bioengineering for the efficient preparation of polyoxygenated terpenoids at the limits of chemical complexity.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23907534 DOI: 10.1126/science.1241606
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728